NCT03091257View on ClinicalTrials.gov

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Dabrafenib

Administered Orally BID

DRUG

Trametinib

Administered Orally once daily

Trial Locations (2)

48201

RECRUITING

Karmanos Cancer Institute, Detroit

02115

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

Barbara Ann Karmanos Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT03091257 - A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter